← Eichor
Study identifier: NCT07175350 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Financial Toxicity (FT) for Radiotherapy (RT) Patients in Italy: a yAIRO (Associazione Italiana Radioterapia e Ocologia Clinica) Multicenter Study

Condition: Oncologic Diseases  ·  Sponsor: Valerio Nardone

PhaseN/A
Planned participants1000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Non- profit, multicenter, prospective, observational study. The study aims to assess financial toxicity (FT) in patients undergoing radiotherapy for oncological diseases, assessed with a validated questionnaire (Patient Reported Outcome for Fighting FInancial Toxicity-PROFFIT- questionnaire).

This description comes directly from the study's public registry record.

Talk to the study team

Roberta Grassi, MD  ·  3333385815  ·  grassi.roberta89@gmail.com

Always discuss trial participation with your own doctor first.

Locations (7)

Radioterapia Oncologica - Ospedale Mons. DimiccoliBarletta, ItalyRecruiting
Unità di Radioterapia - Responsible Research HospitalCampobasso, ItalyRecruiting
Radioterapia oncologica - Ospedale "Vito Fazzi" -Lecce, ItalyRecruiting
AOU "L. Vanvitelli" - UOC RadioterapiaNaples, ItalyRecruiting
.C. Radioterapia - INT G. PascaleNaples, ItalyRecruiting
Radioterapia Oncologica, IRCCS-CROBPotenza, ItalyRecruiting
UOC Radioterapia - Fondazione Policlinico A. GemelliRoma, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07175350